NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DeFi Technologies Inc. (“DeFi Technologies” or the “Company”) (NASDAQ: DEFT) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-06637, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired DeFi Technologies securities between May 12, 2025 and November 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of …

Although public backlash against data centers has been intense over the past twelve months, all of the tech industry's biggest companies have promised additional buildouts of AI infrastructure in the coming year. That includes OpenAI partner Microsoft, which, on Tuesday, announced what it calls a “community-first” approach to AI Infrastructure.

Investors need to pay close attention to BKV stock based on the movements in the options market lately.

Shares of tech giant Amazon.com Inc NASDAQ: AMZN surged more than 10% last week, starting what looks like what could be a decisive run toward November's all-time high. The move hasn't come out of the blue.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025. CoreWeave describes itself as an “an AI cloud computing company.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that CoreWeave, Inc. (NASDAQ: CRWV) Mis.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Trex To Contact Him Directly To Discuss Their Options

Inhibrx Biosciences, Inc. remains a Strong Buy, driven by multiple near-term catalysts, notably the Q2 2026 BLA filing for ozekibart in chondrosarcoma. INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is also advancing in Ewing Sarcoma, with enrollment completion expected Q2 2026 and potential FDA meeting for accelerated approval in H2 2026.

VIENNA, Va.--(BUSINESS WIRE)--Ericsson Federal Technologies Group (Ericsson Federal) is proud to announce the appointment of Nathan Simington as Director of Policy & Strategy. Simington brings exceptional expertise and leadership that will strengthen Ericsson Federal's position in the U.S. Government (USG) and Department of War (DoW) telecommunications and technology sectors. “I am honored to join Ericsson Federal as Director of Policy & Strategy to help accelerate the integration of 5G.

ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction.

Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors should contact the firm.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Venu (VENU) To Contact Him Directly To Discuss Their Options Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Venu (VENU) To Contact Him Directly To Discuss Their Options

On top of their cheap stock prices, the stocks we learn to find earn strong Zacks Ranks, driven by improving earnings outlooks. Wall Street is also very high on these cheap stocks trading for under $10 a share to buy now to start 2026.

Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.

Amazon says it is bringing its “Just Walk Out” checkout technology to temporary retail locations. The company on Tuesday (Jan. 13) announced the debut of the latest iteration of its radio frequency identification (RFID) lanes, designed for things like pop-up shops and festivals.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Paysafe (PSFE) To Contact Him Directly To Discuss Their Options

Dan Ives believes we're still in stage three of ten when it comes to the AI revolution. He talks about why Apple (AAPL) will "continue to bet on Google" to power its AI as Alphabet (GOOGL) hits all-time highs and a $4 trillion market cap.

I assign State Street SPDR S&P Transportation ETF a 'sell' rating, favoring the cap-weighted iShares Transportation Average ETF instead. XTN's equal-weighting scheme results in a lower-quality, higher-risk portfolio with inferior operational efficiency and heightened sensitivity to earnings changes. XTN trades at higher P/E multiples than IYT, with weaker historical and forward growth — forward EPS growth is just 3.08% versus IYT's 13.91%.

Bio-Techne Corporation (TECH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript